Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Memorial Sloan Kettering Cancer Center
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: January 6, 2010
Last updated: August 16, 2016
Last verified: August 2016